These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1910 related articles for article (PubMed ID: 34027555)

  • 41. N6-methyladenosine (m6A) RNA methylation regulator SNRPC is a prognostic biomarker and is correlated with immunotherapy in hepatocellular carcinoma.
    Cai J; Zhou M; Xu J
    World J Surg Oncol; 2021 Aug; 19(1):241. PubMed ID: 34389000
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Computational construction of TME-related lncRNAs signature for predicting prognosis and immunotherapy response in clear cell renal cell carcinoma.
    Zhou L; Fang H; Guo F; Yin M; Long H; Weng G
    J Clin Lab Anal; 2022 Aug; 36(8):e24582. PubMed ID: 35808868
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Identification of a Nine Immune-Related lncRNA Signature as a Novel Diagnostic Biomarker for Hepatocellular Carcinoma.
    Yuan M; Wang Y; Sun Q; Liu S; Xian S; Dai F; Zhang L; Fan Y; Wang F; Yang D; Zheng Y; Deng Z; Tan W; Liu Y; Cheng Y
    Biomed Res Int; 2021; 2021():9798231. PubMed ID: 33506049
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Identification of an m6A-Related Signature as Biomarker for Hepatocellular Carcinoma Prognosis and Correlates with Sorafenib and Anti-PD-1 Immunotherapy Treatment Response.
    Jiang H; Ning G; Wang Y; Lv W
    Dis Markers; 2021; 2021():5576683. PubMed ID: 34221187
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Analysis of m6A-Related lncRNAs for Prognosis Value and Response to Immune Checkpoint Inhibitors Therapy in Hepatocellular Carcinoma.
    Wang Y; Li N; Tian D; Zhou CW; Wang YH; Yang C; Zeng MS
    Cancer Manag Res; 2021; 13():6451-6471. PubMed ID: 34429653
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Prognostic signature based on m6A-related lncRNAs to predict overall survival in pancreatic ductal adenocarcinoma.
    Wu Q; Chen L; Miao D; Jin Y; Zhu Z
    Sci Rep; 2022 Feb; 12(1):3079. PubMed ID: 35197523
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Identification of m6A- and ferroptosis-related lncRNA signature for predicting immune efficacy in hepatocellular carcinoma.
    Xie H; Shi M; Liu Y; Cheng C; Song L; Ding Z; Jin H; Cui X; Wang Y; Yao D; Wang P; Yao M; Zhang H
    Front Immunol; 2022; 13():914977. PubMed ID: 36032107
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Identification of prognostic markers for hepatocellular carcinoma based on the epithelial-mesenchymal transition-related gene BIRC5.
    Xu R; Lin L; Zhang B; Wang J; Zhao F; Liu X; Li Y; Li Y
    BMC Cancer; 2021 Jun; 21(1):687. PubMed ID: 34112092
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Characterization of long non-coding RNAs to reveal potential prognostic biomarkers in hepatocellular carcinoma.
    Ma Y; Luo T; Dong D; Wu X; Wang Y
    Gene; 2018 Jul; 663():148-156. PubMed ID: 29684484
    [TBL] [Abstract][Full Text] [Related]  

  • 50. A Novel Cholesterol Metabolism-Related lncRNA Signature Predicts the Prognosis of Patients with Hepatocellular Carcinoma and Their Response to Immunotherapy.
    Lei H; Xiang T; Zhu H; Hu X
    Front Biosci (Landmark Ed); 2024 Mar; 29(3):129. PubMed ID: 38538256
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Identification of an Oxidative Stress-Related LncRNA Signature for Predicting Prognosis and Chemotherapy in Patients With Hepatocellular Carcinoma.
    Zhong Z; Xu M; Tan J
    Pathol Oncol Res; 2022; 28():1610670. PubMed ID: 36277962
    [No Abstract]   [Full Text] [Related]  

  • 52. Construction of an Immune-Related Six-lncRNA Signature to Predict the Outcomes, Immune Cell Infiltration, and Immunotherapy Response in Patients With Hepatocellular Carcinoma.
    Zhou P; Lu Y; Zhang Y; Wang L
    Front Oncol; 2021; 11():661758. PubMed ID: 34277410
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Construction of an N6-methyladenosine lncRNA- and immune cell infiltration-related prognostic model in colorectal cancer.
    Yu ZL; Zhu ZM
    Protoplasma; 2022 Jul; 259(4):1029-1045. PubMed ID: 34734333
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Long non‑coding RNA‑based risk scoring system predicts prognosis of alcohol‑related hepatocellular carcinoma.
    Luo Y; Ye J; Wei J; Zhang J; Li Y
    Mol Med Rep; 2020 Aug; 22(2):997-1007. PubMed ID: 32468063
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Identification and verification of an immune-related lncRNA signature for predicting the prognosis of patients with bladder cancer.
    Wang J; Shen C; Dong D; Zhong X; Wang Y; Yang X
    Int Immunopharmacol; 2021 Jan; 90():107146. PubMed ID: 33189610
    [TBL] [Abstract][Full Text] [Related]  

  • 56. A somatic mutation-derived LncRNA signatures of genomic instability predicts the prognosis and tumor microenvironment immune characters in hepatocellular carcinoma.
    Jin C; Zhao JS; Huang XQ; Yang XZ; Niu FY; Lin JR; Ma L; Shi YX; Li XS; Jiang P; Gao S; Li F; Song Y
    Hepatol Int; 2022 Oct; 16(5):1220-1233. PubMed ID: 35947245
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Relationships of N6-Methyladenosine-Related Long Non-Coding RNAs With Tumor Immune Microenvironment and Clinical Prognosis in Lung Adenocarcinoma.
    Zhao J; Lin X; Zhuang J; He F
    Front Genet; 2021; 12():714697. PubMed ID: 34777460
    [No Abstract]   [Full Text] [Related]  

  • 58. Immune-related long noncoding RNA signature for predicting survival and immune checkpoint blockade in hepatocellular carcinoma.
    Zhang Y; Zhang L; Xu Y; Wu X; Zhou Y; Mo J
    J Cell Physiol; 2020 Dec; 235(12):9304-9316. PubMed ID: 32330311
    [TBL] [Abstract][Full Text] [Related]  

  • 59. The prognostic value and immune landscapes of m1A/m5C/m6A-associated lncRNA signature in osteosarcoma.
    Wu ZY; Shi ZY
    Eur Rev Med Pharmacol Sci; 2022 Aug; 26(16):5868-5883. PubMed ID: 36066162
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Identification of Five m6A-Related lncRNA Genes as Prognostic Markers for Endometrial Cancer Based on TCGA Database.
    Shan L; Lu Y; Xiang CC; Zhu X; Zuo ED; Cheng X
    J Immunol Res; 2022; 2022():2547029. PubMed ID: 35571565
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 96.